Navigation Links
Boston Scientific Welcomes Publication of Analysis Demonstrating Long-Term Survival Benefit for ICD Therapy
Date:9/28/2010

NATICK, Mass., Sept. 28 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today welcomed the publication of an analysis of long-term data from the MADIT II clinical trial in the current issue of Circulation.  The analysis demonstrates that the life-saving benefits of implantable cardioverter defibrillator (ICD) therapy are sustained at eight years.  This is the first time that long-term data regarding the benefits of ICDs in a primary prevention population have been published in a peer-reviewed journal.  

The analysis shows a sustainable mortality benefit over time, including:

  • At eight years, one life is saved for every eight patients who receive an ICD.  This represents a significant improvement over the two-year MADIT II data, which showed one life saved for every 17 patients.
  • A 34 percent relative reduction in the risk of death for ICD patients at eight years (p<0.001, unadjusted).

  • "ICD therapy has proved effective in patients at risk of sudden cardiac death, and now the long-term MADIT II data show the life-saving benefits of these devices continue over time," said Arthur J. Moss, M.D., Professor of Medicine at the University of Rochester Medical Center and Principal Investigator of the MADIT, MADIT II and MADIT-CRT trials.

    The MADIT II study, sponsored exclusively by Boston Scientific, was designed to determine whether ICDs improve survival when compared to drug therapy alone in heart attack survivors with moderate impairment of the left ventricle, the heart's main pumping chamber.  

    Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.  For more information, please visit: www.bostonscientific.com.  

    Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding new product launches and launch cadence, regulatory approvals, clinical trials, product performance and competitive offerings.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.  

    Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.CONTACT:

    Paul Donovan508-650-8541 (office)508-667-5165 (mobile)Media RelationsBoston Scientific CorporationDavid Knutson651-260-8288 (mobile)Media RelationsBoston Scientific CorporationLarry Neumann508-650-8696 (office)Investor RelationsBoston Scientific Corporation
    '/>"/>

    SOURCE Boston Scientific Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Boston Scientifics TAXUS® Element™ Stent Demonstrates Strong Outcomes in Diabetic Patients
    2. Boston Scientific Announces Clinical Data Supporting Safety and Efficacy of Platinum Chromium PROMUS Element™ Stent
    3. Boston Scientific to Acquire Asthmatx
    4. Boston Scientific Receives Exclusive Expanded Indication for Its CRT-Ds
    5. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
    6. Boston Millennia Partners Portfolio Company CardioMEMS Signs Equity Investment and Exclusive Option to be Acquired for an Additional $375,000,000
    7. Childrens Hospital Boston and Particle Sciences Cooperate on Translational Medicine Efforts
    8. Boston Scientifics Womens Health Products Featured in Studies at the Joint Annual Meeting of the International Continence Society and International Urogynecological Association
    9. Boston Scientific Launches Neuroform EZ(TM) Stent System in U.S. and Europe
    10. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
    11. Cumberland Pharmaceuticals to Present at the Wells Fargo Healthcare Conference in Boston on June 23, 2010
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/11/2017)... 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... Las Piedras, Puerto Rico , where ... Following a comprehensive ... minor structural damage, temporary loss of power and minimal ... completed, manufacturing operations have resumed, and the company expects ...
    (Date:10/10/2017)... EXTON, Pa. , Oct. 10, 2017   ... leader in innovative solutions for injectable drug administration, today ... of West,s ID Adapter for improving the intradermal administration ... the Fourth Skin Vaccination Summit in May 2017 by ... Team Lead, Polio Department, World Health Organization (WHO), and ...
    (Date:10/5/2017)... Ill. , Oct. 5, 2017  In ... Association of Oral and Maxillofacial Surgeons (AAOMS) released ... opioids – to be used as a first-line ... pain. Recognizing ... the AAOMS White Paper "Opioid Prescribing: Acute and ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
    (Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
    (Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
    (Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
    (Date:10/12/2017)... , ... October 12, 2017 , ... Leading pediatric oncology ... in Washington, D.C., for the 49th Congress of the International Society of Paediatric ... President of the Center for Cancer and Blood Disorders at Children’s National, ...
    Breaking Medicine News(10 mins):